AR078193A1 - Proceso para preparar derivados de bencil-benceno sustituidos con glucopiranosilo - Google Patents
Proceso para preparar derivados de bencil-benceno sustituidos con glucopiranosiloInfo
- Publication number
- AR078193A1 AR078193A1 ARP100103544A ARP100103544A AR078193A1 AR 078193 A1 AR078193 A1 AR 078193A1 AR P100103544 A ARP100103544 A AR P100103544A AR P100103544 A ARP100103544 A AR P100103544A AR 078193 A1 AR078193 A1 AR 078193A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- groups
- independently
- organic
- Prior art date
Links
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 239000012074 organic phase Substances 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000007513 acids Chemical class 0.000 abstract 2
- 239000008346 aqueous phase Substances 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 235000012209 glucono delta-lactone Nutrition 0.000 abstract 1
- 229960003681 gluconolactone Drugs 0.000 abstract 1
- 125000005640 glucopyranosyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000002902 organometallic compounds Chemical class 0.000 abstract 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 1
- 239000011541 reaction mixture Substances 0.000 abstract 1
- -1 tetrahydropyran-4-yl Chemical group 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Packaging Of Annular Or Rod-Shaped Articles, Wearing Apparel, Cassettes, Or The Like (AREA)
- Wrapping Of Specific Fragile Articles (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24714409P | 2009-09-30 | 2009-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR078193A1 true AR078193A1 (es) | 2011-10-19 |
Family
ID=43736212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103544A AR078193A1 (es) | 2009-09-30 | 2010-09-29 | Proceso para preparar derivados de bencil-benceno sustituidos con glucopiranosilo |
Country Status (25)
Country | Link |
---|---|
US (2) | US9024010B2 (h) |
EP (1) | EP2486029B1 (h) |
JP (1) | JP5758900B2 (h) |
KR (1) | KR101813025B1 (h) |
CN (1) | CN102574829B (h) |
AR (1) | AR078193A1 (h) |
AU (1) | AU2010303124B2 (h) |
BR (1) | BR112012007085B8 (h) |
CA (1) | CA2775962C (h) |
CL (1) | CL2012000581A1 (h) |
DK (1) | DK2486029T3 (h) |
EA (1) | EA022032B1 (h) |
ES (1) | ES2546762T3 (h) |
HR (1) | HRP20150945T1 (h) |
HU (1) | HUE026133T2 (h) |
IL (1) | IL218101A0 (h) |
IN (1) | IN2012DN02751A (h) |
MX (1) | MX2012003048A (h) |
NZ (1) | NZ598366A (h) |
PH (1) | PH12012500634A1 (h) |
PL (1) | PL2486029T3 (h) |
PT (1) | PT2486029E (h) |
SI (1) | SI2486029T1 (h) |
TW (1) | TWI465458B (h) |
WO (1) | WO2011039108A2 (h) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS52365B (en) * | 2004-03-16 | 2012-12-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
DE602006018961D1 (de) * | 2005-09-08 | 2011-01-27 | Boehringer Ingelheim Pharma | KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZOL, ZUBEREITUNGSVERFAHREN DAFÜR UND DESSEN VERWENDUNG ZUR ARZNEIMITTELHERSTELLUNG |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
JP2010507629A (ja) * | 2006-10-27 | 2010-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 4−(β−D−グルコピラノス−1−イル)−1−メチル−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)−ベンジル]−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用 |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
US8648085B2 (en) | 2007-11-30 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
BRPI0918527A2 (pt) | 2008-09-08 | 2015-12-01 | Boehring Ingelheim Internat Gmbh | compostos para o tratamento de disturbios do cns |
CN102307577A (zh) | 2009-02-13 | 2012-01-04 | 贝林格尔.英格海姆国际有限公司 | 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途 |
NZ594567A (en) | 2009-03-31 | 2013-12-20 | Boehringer Ingelheim Int | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
PT2486029E (pt) | 2009-09-30 | 2015-10-14 | Boehringer Ingelheim Int | Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo |
JP5736377B2 (ja) | 2009-09-30 | 2015-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1−クロロ−4−(β−D−グルコピラノス−1−イル)−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)ベンジル]ベンゼンの結晶形の調製方法 |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
UA110347C2 (uk) | 2010-08-12 | 2015-12-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
EP2714052B1 (en) | 2011-06-03 | 2018-09-19 | Boehringer Ingelheim International GmbH | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2013152476A1 (en) * | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Process for the preparation of benzylbenzene sglt2 inhibitors |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
FI2981269T3 (fi) | 2013-04-04 | 2023-09-27 | Boehringer Ingelheim Vetmedica Gmbh | Aineenvaihduntahäiriöiden hoito hevoseläimillä |
HUE041709T2 (hu) | 2013-04-05 | 2019-05-28 | Boehringer Ingelheim Int | Az empagliflozin terápiás alkalmazásai |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
MX2021004308A (es) | 2013-04-18 | 2022-10-26 | Boehringer Ingelheim Int | Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria. |
ES2605886T3 (es) | 2013-09-27 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Derivados de glucopiranosilo y sus usos en medicina |
HRP20231694T1 (hr) | 2013-12-17 | 2024-03-15 | Boehringer Ingelheim Vetmedica Gmbh | Sglt-2 inhibitor za uporabu u liječenju metaboličkog poremećaja kod životinja iz porodice mačaka |
WO2015101916A1 (en) | 2013-12-30 | 2015-07-09 | Mylan Laboratories Ltd. | Process for the preparation of empagliflozin |
US10603300B2 (en) | 2014-01-23 | 2020-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
CA3187279A1 (en) | 2014-04-01 | 2015-10-08 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
EP4403230A3 (en) | 2014-09-25 | 2025-01-08 | Boehringer Ingelheim Vetmedica GmbH | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
JP2019500477A (ja) | 2016-01-04 | 2019-01-10 | ナショナル テクノロジー アンド エンジニアリング ソリューションズ オブ サンディア, エルエルシー | ディールスアルダーポリフェニレンポリマーの官能化 |
US10053535B2 (en) | 2016-01-04 | 2018-08-21 | National Technology & Engineering Solutions Of Sandia, Llc | Poly(phenylene)-based anion exchange polymers and methods thereof |
US10294325B2 (en) | 2016-01-04 | 2019-05-21 | National Technology & Engineering Solutions Of Sandia, Llc | Halo-containing anion exchange membranes and methods thereof |
EP3526229B1 (en) * | 2016-10-13 | 2021-04-28 | Boehringer Ingelheim International GmbH | Process for preparing glucopyranosyl-substituted benzyl-benzene derivatives |
WO2018073154A1 (en) | 2016-10-19 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
MX2019005435A (es) | 2016-11-10 | 2019-07-10 | Boehringer Ingelheim Int | Composicion farmaceutica, metodos para tratamiento y sus usos. |
CN108794548B (zh) * | 2017-04-28 | 2023-06-16 | 正大天晴药业集团股份有限公司 | 制备恩格列净及其中间体的方法 |
EP3634970B1 (en) | 2017-06-05 | 2023-07-19 | Laurus Labs Limited | Novel process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof |
CN107163033A (zh) * | 2017-06-15 | 2017-09-15 | 扬子江药业集团北京海燕药业有限公司 | 一种高纯度依帕列净的制备方法 |
CN109988161A (zh) * | 2017-12-29 | 2019-07-09 | 徐州万邦金桥制药有限公司 | 一种适合工业化生产恩格列净的制备方法 |
CN108178751A (zh) * | 2018-01-30 | 2018-06-19 | 扬州工业职业技术学院 | 一种恩格列净中间体的合成方法 |
US10479866B1 (en) | 2018-02-28 | 2019-11-19 | National Technology & Engineering Solutions Of Sandia, Llc | Block copolymers including poly(phenylene) and methods thereof |
CN111989103A (zh) | 2018-04-17 | 2020-11-24 | 勃林格殷格翰国际有限公司 | 药物组合物、其治疗方法和用途 |
EP3826642B8 (en) | 2018-07-25 | 2025-06-11 | Boehringer Ingelheim International GmbH | Empagliflozin for use in treating alport syndrome |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
CN109456314A (zh) * | 2018-10-19 | 2019-03-12 | 威海迪素制药有限公司 | 一种恩格列净的制备方法 |
ES2967359T3 (es) | 2018-10-29 | 2024-04-29 | Boehringer Ingelheim Int | Derivados piridinil-sulfonamida, composiciones farmacéuticas y usos de los mismos |
JP7425793B2 (ja) | 2018-10-29 | 2024-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用 |
CN111233915B (zh) * | 2018-11-28 | 2023-09-22 | 上海科胜药物研发有限公司 | 一种2,3,4,6-四-o-三甲基硅基-d-葡萄糖酸内酯的制备方法 |
CN110655511B (zh) * | 2019-05-31 | 2020-10-16 | 北京莱瑞森医药科技有限公司 | 一种高纯度恩格列净的制备和精制方法 |
CN112812107B (zh) * | 2019-11-18 | 2024-03-15 | 上海启讯医药科技有限公司 | 一种sglt-2抑制剂及中间体的制备方法 |
US11759474B2 (en) | 2019-11-28 | 2023-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors in the drying-off of non-human mammals |
CN110759941B (zh) * | 2019-11-29 | 2022-08-30 | 上海网义化工有限公司 | 一种D-葡萄糖酸-γ-内酯及其中间体的制备方法 |
CN110872216A (zh) * | 2019-12-06 | 2020-03-10 | 南京恒道医药科技有限公司 | 一种反应分离耦合生产(2-氯-5-碘苯基)-4-氟苯甲基酮的方法及装置 |
CN110903315A (zh) * | 2019-12-16 | 2020-03-24 | 上海网义化工有限公司 | 一种D-葡萄糖酸-γ-内酯中间体的制备方法 |
CN118615450A (zh) | 2020-02-17 | 2024-09-10 | 勃林格殷格翰动物保健有限公司 | Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途 |
CN115397434A (zh) | 2020-04-07 | 2022-11-25 | 勃林格殷格翰国际有限公司 | 治疗头痛障碍的方法 |
CN111410639B (zh) * | 2020-04-14 | 2021-02-26 | 天津法莫西医药科技有限公司 | 一种恩格列净中间体杂质的制备方法 |
CN112194655B (zh) * | 2020-10-15 | 2022-08-09 | 通化东宝药业股份有限公司 | 一种恩格列净的制备方法 |
KR20220068805A (ko) | 2020-11-19 | 2022-05-26 | 한미약품 주식회사 | 신규한 글루코스 유도체 |
CN113480497B (zh) * | 2021-07-27 | 2023-02-28 | 山东铂源药业股份有限公司 | 一种恩格列净关键中间体的合成方法 |
WO2023006745A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
US20240307426A1 (en) | 2021-07-28 | 2024-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
EP4376829A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
CN114716425B (zh) * | 2022-04-11 | 2023-09-01 | 沧州那瑞化学科技有限公司 | 芳香杂环取代亚甲基的化合物的合成方法 |
WO2023227492A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
CN115231992B (zh) * | 2022-06-30 | 2024-08-27 | 济南鼎皓医药科技有限公司 | 一种(2-氯-5-碘苯基)(4-氟苯基)甲酮的制备方法 |
CN115232179A (zh) * | 2022-08-15 | 2022-10-25 | 江西天戌药业有限公司 | 一种恩格列净中间体杂质的制备方法 |
AU2024233233A1 (en) | 2023-03-06 | 2025-09-11 | Boehringer Ingelheim Vetmedica Gmbh | Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s) |
US20240390332A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan |
WO2024240632A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan |
CN116715569A (zh) * | 2023-05-26 | 2023-09-08 | 雅邦绿色过程与新材料研究院南京有限公司 | 一种4,4’-二氟二苯甲酮的制备方法 |
WO2025191117A1 (en) | 2024-03-15 | 2025-09-18 | Inventiva | Prevention of blood disorders in patient treated with a ppar agonist |
Family Cites Families (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
NL167151C (nl) | 1971-04-09 | 1981-11-16 | Acf Chemiefarma Nv | Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen. |
DE2758025A1 (de) | 1977-12-24 | 1979-07-12 | Bayer Ag | Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung |
NO154918C (no) * | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
JPS5639056A (en) | 1980-07-16 | 1981-04-14 | Kanebo Ltd | Preparation of n,n,n',n'-tetraacylated nucleus halogenated aromatic diamine |
JPS58164502A (ja) | 1982-03-26 | 1983-09-29 | Chugai Pharmaceut Co Ltd | 除草用組成物 |
US4602023A (en) | 1985-06-03 | 1986-07-22 | Warner-Lambert Company | Diphenic acid monoamides |
US4786755A (en) | 1985-06-03 | 1988-11-22 | Warner-Lambert Company | Diphenic acid monoamides |
US4786023A (en) * | 1987-08-19 | 1988-11-22 | Harris Leverett D | Drafting implement holder |
US6297273B1 (en) | 1996-04-02 | 2001-10-02 | Mars, Inc. | Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
JPH1085502A (ja) * | 1996-09-19 | 1998-04-07 | Konica Corp | 晶析方法 |
AU6024998A (en) | 1997-01-15 | 1998-08-07 | Glycomed Incorporated | Aryl c-glycoside compounds and sulfated esters thereof |
JPH11124392A (ja) | 1997-10-21 | 1999-05-11 | Sankyo Co Ltd | C−グリコシル化されたアリールスズ化合物 |
DE19846314A1 (de) | 1998-10-08 | 2000-04-13 | Basf Ag | Polyolefinnanocomposite |
US6613806B1 (en) * | 1999-01-29 | 2003-09-02 | Basf Corporation | Enhancement of the efficacy of benzoylbenzenes |
ES2216937T3 (es) | 1999-08-31 | 2004-11-01 | Kissei Pharmaceutical Co., Ltd. | Derivados de glucopiranosiloxipirazol, composiciones medicinales que los contienen e intermedios obtenidos durante su preparacion. |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6498193B2 (en) | 1999-12-22 | 2002-12-24 | Trustees Of Dartmouth College | Treatment for complications of type 2 diabetes |
US6627611B2 (en) * | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
JP4456768B2 (ja) | 2000-02-02 | 2010-04-28 | 壽製薬株式会社 | C−配糖体を含有する薬剤 |
TR200202200T2 (tr) * | 2000-03-17 | 2002-12-23 | Kissei Pharmaceutical Co., Ltd. | Glükopiranosiloksibenzilbenzen türevleri, bu türevleri ihtiva eden tıbbi bileşimler ve türevlerin hazırlanması için ara-maddeler. |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
AU9025701A (en) | 2000-09-29 | 2002-04-15 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containingthe same |
EP1344780A4 (en) | 2000-11-30 | 2004-01-28 | Kissei Pharmaceutical | GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION |
TWI255817B (en) * | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
WO2002064549A1 (en) | 2001-02-15 | 2002-08-22 | Pfizer Products Inc. | Ppar agonists |
US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
JP3698067B2 (ja) * | 2001-03-30 | 2005-09-21 | Jsr株式会社 | 電子吸引性基および電子供与性基を有するモノマー、それを用いた共重合体、ならびにプロトン伝導膜 |
EP1385856B1 (en) | 2001-04-11 | 2006-02-22 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
DE10139416A1 (de) | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
WO2003031458A1 (en) | 2001-10-12 | 2003-04-17 | Dana-Farber Cancer Institute | Methods for synthesis of diarylmethanes |
ES2292931T3 (es) | 2002-02-01 | 2008-03-16 | Novo Nordisk A/S | Amidas de azetidinas, pirrolidinas, piperidinas y azepanos aminoalquilo sustituidos. |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
ES2345250T3 (es) * | 2002-08-08 | 2010-09-20 | Kissei Pharmaceutical Co., Ltd. | Derivado de pirazol en la composicion medicinal que contiene el mismo, el uso medicinal del mismo, y un intermedio para la produccion del mismo. |
ATE453644T1 (de) | 2002-08-21 | 2010-01-15 | Boehringer Ingelheim Pharma | 8-[3-amino-piperidin-1-yl] -xanthine, deren herstellung und deren verwendung als arzneimittel |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
JP3567162B1 (ja) | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | 4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用 |
DK1564210T5 (da) | 2002-11-20 | 2010-05-03 | Japan Tobacco Inc | 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer |
JP4651934B2 (ja) | 2002-12-04 | 2011-03-16 | キッセイ薬品工業株式会社 | ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途 |
DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
CA2512389A1 (en) | 2003-01-03 | 2004-07-29 | Bristol-Myers Squibb Company | Methods of producing c-aryl glucoside sglt2 inhibitors |
EP1597266A4 (en) | 2003-02-27 | 2008-02-20 | Bristol Myers Squibb Co | NON-CRYOGENIC PROCESS FOR THE PRODUCTION OF GLYCOSIDES |
TWI310033B (en) | 2003-03-14 | 2009-05-21 | Yamanouchi Pharma Co Ltd | C-glycoside derivatives or salts thereof |
US7674486B2 (en) | 2003-05-14 | 2010-03-09 | Indus Biotech Pvt. Ltd. | Synergistic composition for the treatment of diabetes mellitus |
WO2005000860A2 (en) * | 2003-06-03 | 2005-01-06 | The Regents Of The University Of California | Compositions and methods for treatment of disease with acetylated disaccharides |
JP2004359630A (ja) | 2003-06-06 | 2004-12-24 | Yamanouchi Pharmaceut Co Ltd | ジフルオロジフェニルメタン誘導体及びその塩 |
CA2549015A1 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted fused heterocyclic c-glycosides |
EA010299B1 (ru) | 2003-08-01 | 2008-08-29 | Мицубиси Танабе Фарма Корпорейшн | Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортёра |
EA010655B1 (ru) | 2003-08-01 | 2008-10-30 | Янссен Фармацевтика Н.В. | Замещенные индазол-о-глюкозиды |
JP4131216B2 (ja) | 2003-08-20 | 2008-08-13 | Jsr株式会社 | ポリアリーレンおよびその製造方法、ならびに高分子固体電解質およびプロトン伝導膜 |
DE502004008951D1 (de) | 2003-08-26 | 2009-03-19 | Boehringer Ingelheim Pharma | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US7375090B2 (en) * | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
US20050085680A1 (en) * | 2003-10-21 | 2005-04-21 | Joseph Auerbach | Method for industrial decontamination |
US7371732B2 (en) * | 2003-12-22 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture |
DE10361133A1 (de) | 2003-12-22 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
WO2005085237A1 (ja) | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
US7732596B2 (en) | 2004-03-04 | 2010-06-08 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
RS52365B (en) * | 2004-03-16 | 2012-12-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
DE102004012676A1 (de) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US7393836B2 (en) * | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
KR20070048188A (ko) | 2004-07-08 | 2007-05-08 | 아스텔라스세이야쿠 가부시키가이샤 | 아줄렌 유도체의 제조방법 및 이의 합성 중간체 |
DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
WO2006010557A1 (de) | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
JP5046370B2 (ja) | 2004-09-29 | 2012-10-10 | キッセイ薬品工業株式会社 | 1−(β−D−グリコピラノシル)−3−置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途 |
DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
JP2008524162A (ja) | 2004-12-16 | 2008-07-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法 |
JP2006176443A (ja) | 2004-12-22 | 2006-07-06 | Shionogi & Co Ltd | メラニン凝集ホルモン受容体アンタゴニスト |
GB0428180D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Combination therapy |
GT200600008A (es) | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
JP5264183B2 (ja) | 2005-02-23 | 2013-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換((ヘテロ)アリールエチニル−ベンジル)−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体2(sglt2)インヒビターとしてのそれらの使用 |
JP5238492B2 (ja) * | 2005-04-15 | 2013-07-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sgltインヒビターとしてのグルコピラノシル置換(ヘテロアリールオキシ−ベンジル)−ベンゼン誘導体 |
UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7772191B2 (en) * | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
WO2007000445A1 (en) | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
TW200733966A (en) * | 2005-07-27 | 2007-09-16 | Boehringer Ingelheim Int | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
KR100780553B1 (ko) | 2005-08-18 | 2007-11-29 | 한올제약주식회사 | 메트포르민 서방정 및 그의 제조방법 |
US7452872B2 (en) | 2005-08-24 | 2008-11-18 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
WO2007025943A2 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
DE602006018961D1 (de) | 2005-09-08 | 2011-01-27 | Boehringer Ingelheim Pharma | KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZOL, ZUBEREITUNGSVERFAHREN DAFÜR UND DESSEN VERWENDUNG ZUR ARZNEIMITTELHERSTELLUNG |
AR056195A1 (es) * | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
JOP20180109A1 (ar) | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
JP2009510007A (ja) | 2005-09-30 | 2009-03-12 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | メロキシカムを含む医薬調製 |
TW200801029A (en) | 2006-02-15 | 2008-01-01 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
PE20080697A1 (es) * | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (es) * | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
ES2523729T3 (es) | 2006-06-16 | 2014-12-01 | Lek Pharmaceuticals D.D. | Composición farmacéutica que comprende hidroclorotiazida y telmisartán |
PE20120542A1 (es) | 2006-06-27 | 2012-05-14 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
WO2008020011A1 (en) | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
EP2056673A4 (en) | 2006-08-17 | 2010-06-16 | Wellstat Therapeutics Corp | COMBINATION TREATMENT FOR METABOLISM DISEASES |
US7858587B2 (en) * | 2006-09-21 | 2010-12-28 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture |
JP2010507629A (ja) * | 2006-10-27 | 2010-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 4−(β−D−グルコピラノス−1−イル)−1−メチル−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)−ベンジル]−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用 |
CA2668623A1 (en) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
MX2009004104A (es) * | 2006-11-09 | 2009-06-16 | Boehringer Ingelheim Int | Terapia combinada con inhibidores de sglt-2 y sus composiciones farmaceuticas. |
WO2008062273A2 (en) | 2006-11-20 | 2008-05-29 | Cadila Pharmaceuticals Limited | Solid oral dosage form having antidiabetic drug combination |
TW200838549A (en) | 2007-01-26 | 2008-10-01 | Boehringer Ingelheim Int | Methods for preventing and treating neurodegenerative disorders |
EP2114937B1 (de) | 2007-01-26 | 2011-06-29 | Sanofi-Aventis | Phenothiazin derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2008101938A1 (en) | 2007-02-21 | 2008-08-28 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
JP2010519273A (ja) * | 2007-02-21 | 2010-06-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法 |
ITFI20070042A1 (it) | 2007-02-21 | 2008-08-22 | Laboratori Guidotti Spa | Formulazione farmaceutica e compressa comprendente detta formulazione. |
AR065809A1 (es) * | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
TW200904454A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
US20080287529A1 (en) * | 2007-05-18 | 2008-11-20 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
CL2008002425A1 (es) * | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
HUE035130T2 (en) * | 2007-09-10 | 2018-05-02 | Janssen Pharmaceutica Nv | A method for preparing compounds useful as SGLT inhibitors |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
EP2249643A4 (en) | 2008-02-05 | 2013-10-09 | Merck Sharp & Dohme | PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE IV HEMMER |
US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
JPWO2009123194A1 (ja) | 2008-04-01 | 2011-07-28 | 武田薬品工業株式会社 | 複素環化合物 |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
WO2010045656A2 (en) | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
EP2396005A1 (en) * | 2009-02-13 | 2011-12-21 | Boehringer Ingelheim International GmbH | Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabete mellitus, impaired glucose tolerance or hyperglycemia |
NZ594044A (en) | 2009-02-13 | 2014-08-29 | Boehringer Ingelheim Int | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
CN102307577A (zh) | 2009-02-13 | 2012-01-04 | 贝林格尔.英格海姆国际有限公司 | 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途 |
UA105033C2 (uk) | 2009-02-13 | 2014-04-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Фармацевтична композиція, що включає глюкопіранозилзаміщене похідне бензолу, фармацевтична дозована форма, що містить зазначене похідне, їх застосування для лікування метаболічного порушення |
MY182720A (en) | 2009-04-16 | 2021-02-03 | Taisho Pharmaceutical Co Ltd | Pharmaceutical compositions |
EP2435033A1 (en) | 2009-05-27 | 2012-04-04 | Bristol-Myers Squibb Company | Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof |
US20110077212A1 (en) | 2009-09-25 | 2011-03-31 | Theracos, Inc. | Therapeutic uses of sglt2 inhibitors |
JP5736377B2 (ja) | 2009-09-30 | 2015-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1−クロロ−4−(β−D−グルコピラノス−1−イル)−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)ベンジル]ベンゼンの結晶形の調製方法 |
PT2486029E (pt) | 2009-09-30 | 2015-10-14 | Boehringer Ingelheim Int | Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
CN104825417A (zh) | 2009-11-13 | 2015-08-12 | 阿斯利康(瑞典)有限公司 | 立即释放片剂 |
WO2011120923A1 (en) | 2010-03-30 | 2011-10-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
MX2013002146A (es) | 2010-09-03 | 2013-04-03 | Astrazeneca Uk Ltd | Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua. |
US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
EP2670397B1 (en) | 2011-02-01 | 2020-05-13 | Bristol-Myers Squibb Company | Pharmaceutical formulations including an amine compound |
US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
EP2714052B1 (en) | 2011-06-03 | 2018-09-19 | Boehringer Ingelheim International GmbH | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
DE102011109492A1 (de) | 2011-08-04 | 2013-02-07 | GM Global Technology Operations LLC (n. d. Gesetzen des Staates Delaware) | Fahrunterstützungsvorrichtung zur Unterstützung der Befahrung enger Fahrwege |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
HUE041709T2 (hu) | 2013-04-05 | 2019-05-28 | Boehringer Ingelheim Int | Az empagliflozin terápiás alkalmazásai |
US20160000816A1 (en) | 2013-04-05 | 2016-01-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
MX2021004308A (es) | 2013-04-18 | 2022-10-26 | Boehringer Ingelheim Int | Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria. |
CA3187279A1 (en) | 2014-04-01 | 2015-10-08 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
WO2017064193A1 (en) | 2015-10-15 | 2017-04-20 | Boehringer Ingelheim International Gmbh | Sglt-2 inhibitor for use in the treatment of a metabolic myopathy |
-
2010
- 2010-09-24 PT PT107628992T patent/PT2486029E/pt unknown
- 2010-09-24 CN CN201080042705.XA patent/CN102574829B/zh active Active
- 2010-09-24 EA EA201200537A patent/EA022032B1/ru not_active IP Right Cessation
- 2010-09-24 IN IN2751DEN2012 patent/IN2012DN02751A/en unknown
- 2010-09-24 BR BR112012007085A patent/BR112012007085B8/pt active IP Right Grant
- 2010-09-24 PH PH1/2012/500634A patent/PH12012500634A1/en unknown
- 2010-09-24 WO PCT/EP2010/064120 patent/WO2011039108A2/en active Application Filing
- 2010-09-24 NZ NZ598366A patent/NZ598366A/en unknown
- 2010-09-24 JP JP2012531333A patent/JP5758900B2/ja active Active
- 2010-09-24 EP EP10762899.2A patent/EP2486029B1/en active Active
- 2010-09-24 DK DK10762899.2T patent/DK2486029T3/en active
- 2010-09-24 ES ES10762899.2T patent/ES2546762T3/es active Active
- 2010-09-24 AU AU2010303124A patent/AU2010303124B2/en active Active
- 2010-09-24 HU HUE10762899A patent/HUE026133T2/en unknown
- 2010-09-24 HR HRP20150945TT patent/HRP20150945T1/hr unknown
- 2010-09-24 SI SI201031009T patent/SI2486029T1/sl unknown
- 2010-09-24 CA CA2775962A patent/CA2775962C/en active Active
- 2010-09-24 KR KR1020127008072A patent/KR101813025B1/ko active Active
- 2010-09-24 PL PL10762899T patent/PL2486029T3/pl unknown
- 2010-09-28 US US12/892,326 patent/US9024010B2/en active Active
- 2010-09-29 AR ARP100103544A patent/AR078193A1/es active IP Right Grant
- 2010-09-29 TW TW099133084A patent/TWI465458B/zh active
- 2010-10-20 MX MX2012003048A patent/MX2012003048A/es active IP Right Grant
-
2012
- 2012-02-14 IL IL218101A patent/IL218101A0/en active IP Right Grant
- 2012-03-02 CL CL2012000581A patent/CL2012000581A1/es unknown
-
2015
- 2015-04-07 US US14/680,318 patent/US9873714B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR078193A1 (es) | Proceso para preparar derivados de bencil-benceno sustituidos con glucopiranosilo | |
PE20091582A1 (es) | Procedimiento para la preparacion de dihidropteridinonas | |
ES2557465T3 (es) | Moduladores de la actividad de HEC 1 y procedimientos para ello | |
RS52740B (en) | PROCESS FOR PREPARING UNITS USEFUL AS SGLT INHIBITORS | |
AR083542A1 (es) | Piperidin-4-il-azetidin diamidas como inhibidores de monoacilglicerol lipasa | |
PE20050948A1 (es) | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv | |
PE20040844A1 (es) | Acidos fenilaceticos y derivados como inhibidores de la cox-2 | |
ES2583642T3 (es) | Composiciones y métodos para la inhibición de la ruta de JAK | |
CO6382182A2 (es) | Proceso para la preparación de benzonorbornen-5-il-amidas del ácido pirazolil-4-carboxílico. | |
CO6341623A2 (es) | Compuestos organicos | |
CU24316B1 (es) | Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen | |
AR077598A1 (es) | Compuestos heterociclicos fusionados como modulares de canales ionicos | |
AR083180A1 (es) | Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa | |
AR057836A1 (es) | Piperizinas como agentes contra la malaria | |
BR112012024403A2 (pt) | processo de preparo de derivados de amino-benzofurano | |
AR059296A1 (es) | Compuesto de l-tartrato de s-zopiclona y proceso para resolver los enantiomeros de zopiclona. | |
AR066709A1 (es) | Proceso para la produccion de pirazoles | |
MX2016005829A (es) | Procedimiento para la preparacion de iopamidol. | |
CO6501175A2 (es) | Derivados de benzotiazinas, su preparación y aplicación como fármacos | |
PE20120223A1 (es) | Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1) | |
ES2559854T3 (es) | Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica | |
Huang et al. | A facile synthesis of β-amino carbonyl compounds through an aza-Michael addition reaction under solvent-free conditions | |
AR071217A1 (es) | Derivados bencimidazol | |
Yue et al. | Direct Synthesis Sulfonamides from Nitroarenes and Sulfonyl Chlorides in Water | |
PE20090771A1 (es) | Derivados de cinolina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |